| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Renal/Genitourinary System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Renal/Genitourinary System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Renal/Genitourinary System |
Recent Updates
Recently added Catalysts
Vera Therapeutics, Inc.$42
-0.61 (-1.44%)
B 62Pipeline Score Fair Value Biotech · Commercial
Market Cap
2.44 B
EPS
-5.55
P/E Ratio
-
Value Trade
30.73 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
86.01 M
Operating CF
-106.50 M
Total Assets
621.74 M
Total Liabilities
122.04 M
Equity
499.70 M
D/E Ratio
12,345
-12.27 %
Week
-15.87 %
1 Month
-18.53 %
3 Month
23.74 %
6 Month
85.1 %
5 Year
198.33 %
All Time
Cash Data
Cash Position
596.76 M
Monthly Burn
35.50 M
Runway
14.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
3.40 M
52 Week Range
18.76 - 56.05
% held by Insiders
18.55 %
% held by Institutions
91.13 %
Enterprise Value
1.92 B
Total Shares
71.81 M
Short %
20.25 %
Float Shares
62.98 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vera Therapeutics, Inc.
274Total events
6Upcoming
78Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 6
TBD
T2Oral Presentation
Management to present and participate in one-on-one meetings at upcoming investor conferences
Event history 268
Jul 9, 2026
Jul 7, 2026
◆PDUFA DateAtaciceptApprovedRegulatory Filing
PDUFA target action date for atacicept BLA
IgA Nephropathy (IgAN)source ↗
Jul 7, 2026
◆FDA ApprovalAtaciceptApprovedFDA Decision
Potential FDA accelerated approval of atacicept in IgAN
IgA Nephropathy (IgAN)source ↗
Jul 7, 2026
▲FDA ApprovalTRUTAKNAApprovedFDA Decision
FDA accelerated approval for TRUTAKNA in IgAN
primary IgA nephropathysource ↗
Jul 7, 2026
▲Topline ReadoutTRUTAKNAApprovedClinical Data
Topline results from prespecified 36-week interim analysis of ORIGIN 3
primary IgA nephropathysource ↗
Jul 7, 2026
▲Primary Endpoint MetTRUTAKNAApprovedClinical Data
Primary endpoint met in ORIGIN 3 interim analysis
primary IgA nephropathysource ↗
Jul 7, 2026
▲Secondary Endpoint DataTRUTAKNAApprovedClinical Data
Secondary endpoint of Gd-IgA1 reduction reported
primary IgA nephropathysource ↗
Jul 7, 2026
●Oral PresentationTRUTAKNAApprovedPresentation
Investor webcast on accelerated approval
primary IgA nephropathysource ↗
Q3 2026
◆Topline ReadoutAtaciceptApprovedClinical Data
Revised ORIGIN 3 eGFR analysis results expected Q3 2026
IgA Nephropathysource ↗
Q3 2026
◆Topline ReadoutTRUTAKNAApprovedClinical Data
eGFR confirmatory results anticipated
primary IgA nephropathysource ↗
Q3 2026
◆Timing GuidanceTRUTAKNAApprovedPresentation
Confirmatory eGFR results anticipated in Q3 2026
primary IgA nephropathysource ↗
Drug Pipeline Intelligence
B62
Pipeline Score $3.5B
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.4x
rNPV / MCap Top 89%
Small Cap (rank 101 of 911)
Percentile RankVera Therapeutics, Inc. holds a solid B-grade pipeline (62/100), with $5.4B risk-adjusted pipeline value, led by Atacicept in IgA Nephropathy (Phase 3), across $106B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atacicept Monoclonal antibody | IgA Nephropathy | Phase 3 | NCT04716231 | 90% | $3.5B | ACTIVE NOT_RECRUITING | 376 | AVERAGE | C (59) | Jul 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Atacicept BreakthroughPriorityAccelerated | — | — | 2025-11-06 | UPCR reduction: 42%; Gd Ig A1 reduction: -68%; hematuria resolution odds ratio: 19.1 Read More | Primary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received 1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed u Read More | |
Atacicept BreakthroughPriorityAccelerated | — | — | 2025-11-06 | UPCR reduction: 42%; Gd Ig A1 reduction: -68%; hematuria resolution odds ratio: 19.1 Read More | Primary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received 1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed u Read More | |
Atacicept BreakthroughPriorityAccelerated | — | — | 2025-11-06 | UPCR reduction: 42%; Gd Ig A1 reduction: -68%; hematuria resolution odds ratio: 19.1 Read More | Primary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received 1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed u Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VERA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VERA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VERA▼ -1.4%today
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics announced the retirement of William Turner as Chief Regulatory Officer, transitioning him to a Strategic Advisor role. Nancy Boman, with over 25 years of regulatory experience, will succeed him. This leadership change follows the recent accelerated approval of TRUTAKNA for IgA nephropathy, marking a significant milestone for the company.
Read more →VERA▼ -1.4%today
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Vera Therapeutics has received FDA accelerated approval for TRUTAKNA, the first therapy targeting both BAFF and APRIL for adults with primary IgA nephropathy (IgAN). In the ORIGIN 3 trial, TRUTAKNA demonstrated a 46% reduction in proteinuria compared to baseline and a 42% reduction compared to placebo. While generally well tolerated, the long-term impact on kidney function is yet to be established, and ongoing trials will determine continued approval.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced that it granted inducement awards to ten new employees, consisting of stock options and restricted stock units (RSUs) under its 2024 Inducement Plan. The awards, which total 28,800 stock options and 14,150 RSUs, were approved by the Compensation Committee to incentivize employee retention and hiring. Each stock option has an exercise price equal to the company’s closing price as of June 2, 2026. The vesting schedule spans over four years, aimed at fostering long-term commitment from new hires.
Read more →VERA▼ -7.9%on this newsshared move
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics has aligned with the FDA to conduct an earlier analysis of eGFR for atacicept, aimed at supporting its full approval for treating IgA Nephropathy. The revised analysis is now scheduled for Q3 2026, with a supplemental Biologics License Application planned for Q4 2026. The ORIGIN Phase 2b trial showed significant results, indicating the potential of atacicept as a leading therapy in this area.
Read more →VERAVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics reported a business update and financial results for Q1 2026, highlighting FDA's priority review of atacicept for IgA Nephropathy with a PDUFA date set for July 7, 2026. The company is preparing for a U.S. commercial launch of atacicept in mid-2026, supported by a strong balance sheet. However, the company reported a significant increase in net loss compared to the previous year.
Read more →VERAVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12-14, 2026. The management team is scheduled to speak on May 13 at 4:20 PM PDT and will also hold one-on-one investor meetings. The company focuses on innovative treatments for serious immunological diseases.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 27, 2026
Vera Therapeutics announced inducement grants for its new Chief Legal Officer, Jane Wright-Mitchell, consisting of stock options and restricted stock units. The awards, totaling 56,850 stock options and 42,403 RSUs, are part of the company's 2024 Inducement Plan and aim to incentivize the new hire. The stock options will vest over four years, aligning with the company's strategy to attract top talent.
Read more →VERAVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately. With over 25 years of experience in the life sciences sector, she will lead legal efforts as the company approaches the launch of its dual BAFF/APRIL inhibitor for IgA nephropathy. Her previous roles include General Counsel at Vaxcyte, Inc., and she aims to strengthen Vera's foundation for sustainable success.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
Vera Therapeutics announced inducement grants for six new employees, consisting of stock options and restricted stock units. The awards are part of the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $39.30 and will vest over four years. Vera Therapeutics focuses on developing treatments for serious immunological diseases.
Read more →VERAVera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics has appointed Christopher Hite to its Board of Directors, bringing extensive experience in corporate and financial strategy within the biopharmaceutical sector. This appointment comes as the company prepares for the potential launch of its dual BAFF/APRIL inhibitor, atacicept, aimed at treating IgA nephropathy. Hite's leadership is expected to contribute significantly to the company's growth and success.
Read more →VERAVera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Vera Therapeutics has reported its business highlights and financial results for 2025, showcasing advancements in its lead product, atacicept, which is nearing potential FDA approval. The company anticipates a commercial launch in mid-2026 if approved. Despite a significant net loss, Vera remains confident in the efficacy of atacicept for treating IgAN and other autoimmune diseases.
Read more →VERAVera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics announced its participation in upcoming investor conferences, where management will present and hold one-on-one meetings. The company focuses on developing treatments for serious immunological diseases, with notable products like atacicept and VT-109. A replay of a recent fireside chat will be available on their website for 90 days.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
Vera Therapeutics announced inducement grants for two new employees, including stock options and restricted stock units. The grants are part of the company's 2024 Inducement Plan and aim to attract talent as it continues to develop treatments for serious immunological diseases. The stock options have an exercise price of $45.28 and will vest over four years.
Read more →VERAVera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
Vera Therapeutics has appointed Matt Skelton as Chief Commercial Officer to lead the company's commercial launch of atacicept for IgA nephropathy. Skelton, who has extensive experience in biotech commercialization, aims to guide the company through its transition to a commercial-stage entity. Atacicept has shown promising results in clinical trials and has received Breakthrough Therapy Designation from the FDA.
Read more →VERAVera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Vera Therapeutics announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12-15, 2026, in San Francisco. The management team will present on January 13 and engage in one-on-one investor meetings, promoting their innovative treatments for serious immunologic diseases. Vera's lead product, atacicept, targets autoimmune diseases, and the company also holds an exclusive license for a novel fusion protein with therapeutic potential across B-cell-mediated diseases.
Read more →VERAVera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
Vera Therapeutics announced that the FDA has accepted its Biologics License Application for atacicept, aimed at treating adults with IgA nephropathy. The application is under Priority Review, with a target action date set for July 7, 2026. The drug demonstrated significant efficacy in reducing proteinuria in clinical trials, marking a potential advancement in treatment options for this serious condition.
Read more →VERAVera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
Vera Therapeutics has announced the pricing of a public offering of 6,138,108 shares of its Class A common stock at $42.50 per share, expected to generate gross proceeds of approximately $261 million. The offering's closing is anticipated on December 11, 2025, subject to customary conditions. This funding aims to support the company's development of treatments for serious immunologic diseases, including its lead product candidate, atacicept. Major financial institutions are involved as joint managers for the offering.
Read more →VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
Vera Therapeutics announced the granting of inducement awards to seven new employees under its 2024 Inducement Plan. The awards consist of non-qualified stock options for 42,000 shares and restricted stock units for 21,000 shares, with a vesting schedule over four years. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention and attract talent.
Read more →VERAVera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Vera Therapeutics has announced its intention to initiate a public offering of $200 million in Class A common stock. This move aims to support its ongoing development of therapies for serious immunologic diseases. The offering is subject to market conditions, and there is no guarantee regarding its completion or terms. J.P. Morgan, Goldman Sachs, Evercore, and Cantor are among the managers involved in the offering.
Read more →VERAVera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
Vera Therapeutics has appointed James R. Meyers to its Board of Directors, bringing over 30 years of biopharmaceutical experience. Meyers' expertise is expected to support the upcoming launch of atacicept, a dual BAFF/APRIL inhibitor aimed at treating IgA nephropathy and other autoimmune diseases. The company is poised for significant growth as it transitions into a commercial organization.
Read more →VERA▲ +14.7%on this news
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
Vera Therapeutics will present at the TD Cowen Immunology & Inflammation Summit on November 13, 2025. The management team will also hold one-on-one meetings with investors. The company is dedicated to developing innovative treatments for serious immunological diseases, including its lead product candidate, atacicept.
Read more →VERA▲ +14.7%on this newsshared move
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Vera Therapeutics has submitted a Biologics License Application to the FDA for atacicept, aimed at treating adults with IgA nephropathy. The submission is based on positive interim results from the ORIGIN 3 trial, which demonstrated a significant reduction in proteinuria. Atacicept is positioned as a potential breakthrough treatment for this serious autoimmune kidney disease.
Read more →VERA▲ +6.6%on this news· ran to +26% by day 3shared move
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
Vera Therapeutics announced positive results from the ORIGIN Phase 3 trial of atacicept for IgA nephropathy, showing a significant reduction in proteinuria and favorable safety profile. The findings were presented at ASN Kidney Week 2025 and published in NEJM. The company plans to submit a BLA to the FDA for atacicept, aiming for a commercial launch in 2026.
Read more →VERAPrimary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received 1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed u
An interim analysis of the trial for Atacicept showed a 42% reduction in UPCR from baseline after 36 weeks, indicating promising efficacy in patients. The analysis included 203 participants who received Atacicept or placebo, revealing consistent efficacy across prespecified subgroups and generally favorable safety. Serious adverse events were lower in the Atacicept group, but some participants reported injection site reactions. No deaths occurred during the study, supporting the treatment's tolerability.
Read more →VERAVera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Vera Therapeutics reported its third quarter 2025 financial results, highlighting a net loss of $80.3 million. The company is preparing to submit a Biologics License Application (BLA) for atacicept, supported by data from the ORIGIN trials. Atacicept has received FDA Breakthrough Therapy Designation for treating IgAN, with further data to be shared at ASN Kidney Week.
Read more →VERAVera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
Vera Therapeutics will hold an investor call on November 6, 2025, to discuss the ORIGIN Phase 3 trial results of atacicept for IgA nephropathy. The call will feature insights from leading nephrology experts and will include a Q&A session. The ORIGIN trial has shown statistically significant reductions in proteinuria, indicating atacicept's potential as a treatment option.
Read more →VERAVera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
Vera Therapeutics announced that data from the ORIGIN Phase 3 trial of atacicept will be presented at ASN Kidney Week 2025. The trial demonstrated significant reductions in proteinuria, indicating potential benefits for patients with IgA nephropathy. Atacicept has also received FDA Breakthrough Therapy Designation, highlighting its promising clinical profile.
Read more →VERAVera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results • On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025;
Vera Therapeutics has reported its second-quarter financial results for 2025, highlighting a planned submission of a Biologics License Application for atacicept to the U.S. FDA by Q4 2025. The company announced positive findings from the ORIGIN Phase 3 trial and has initiated a new trial (PIONEER) targeting a wider patient population. Despite a growing cash runway bolstered by a new credit facility, the company reported a significant net loss compared to the previous year, raising concerns about financial sustainability amid clinical and regulatory efforts.
Read more →VERAVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. has announced inducement grants of stock options and restricted stock units to fifteen new employees under Nasdaq Listing Rule 5635(c)(4). The grants include non-qualified stock options for 133,500 shares and restricted stock units for 73,695 shares, with a vesting period of four years. This initiative aims to strengthen the company by attracting talented individuals to support its mission in developing treatments for serious immunological diseases. Vera's lead product candidate, atacicept, targets autoimmune diseases, and the company has retained global rights for its development.
Read more →VERAVera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Vera Therapeutics, Inc. has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach from June 9 to 11, 2025. The company's management team will engage in a fireside chat and one-on-one investor meetings during the event. Vera Therapeutics specializes in developing treatments for serious immunological diseases, with its lead candidate, atacicept, targeting autoimmune conditions like IgAN and lupus nephritis. The company retains global rights to its key product candidates, including MAU868 for BK virus infections.
Read more →VERAVera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
Vera Therapeutics has successfully secured a new credit facility of up to $500 million with Oxford Finance, replacing an existing $50 million facility. This refinancing is marked by lowered interest rates and increased capital availability, which enhances Vera's financial flexibility. The company plans to submit a Biologics License Application (BLA) for its lead product, atacicept, targeting IgA nephropathy by the fourth quarter of 2025, potentially advancing treatment standards in the field. Overall, this strategic move positions Vera favorably for future growth and commercial endeavors.
Read more →VERA▲ +67.5%on this newsshared move
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) a
Vera Therapeutics has announced that its investigational drug atacicept has successfully met its primary endpoint in the ORIGIN Phase 3 trial for the treatment of IgA nephropathy. Participants treated with atacicept demonstrated a statistically significant 46% reduction in proteinuria compared to the baseline and a 42% reduction compared to placebo. The favorable safety profile of atacicept is comparable to that of the placebo group. Vera aims to submit a Biologics License Application (BLA) for atacicept to the FDA, which could pave the way for its approval and subsequent launch in 2026.
Read more →VERA▼ -13.8%on this newsshared move
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results • On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (I
Vera Therapeutics has provided a business update and reported financial results for Q1 2025, highlighting its progress towards the pivotal Phase 3 ORIGIN trial results for atacicept in IgA Nephropathy, expected in 2Q 2025. The company is also planning to submit a Biologics License Application for this treatment by the end of 2025. Despite reporting a significant net loss for the quarter, Vera is expanding its atacicept program into various autoimmune kidney diseases, indicating a focus on growth and innovation in immunological therapy development.
Read more →VERAVera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
Vera Therapeutics, Inc. has completed full enrollment in its pivotal ORIGIN Phase 3 trial for atacicept, aimed at treating IgA Nephropathy (IgAN), with 431 participants enrolled. The company plans to announce primary efficacy endpoint results this quarter and aims for a Biologics License Application (BLA) submission for accelerated approval by the second half of 2025. Atacicept has shown promising results in previous trials, indicating potential for a groundbreaking treatment option for patients with IgAN.
Read more →VERA▲ +5.9%on this news
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Vera Therapeutics Inc. will participate in the TD Cowen 45th Annual Health Care Conference held in Boston, MA from March 3-5, 2025. The company's management team is set to engage in a fireside chat and conduct one-on-one meetings with investors. Vera focuses on developing treatments for serious immunological diseases, particularly its lead candidate, atacicept. This event presents an opportunity for the company to showcase its innovations in the field and attract potential investment.
Read more →VERAVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results • On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA
Vera Therapeutics provided a business update, reporting an upcoming primary endpoint result from the pivotal Phase 3 ORIGIN trial for atacicept in IgA Nephropathy set to be announced in Q2 2025. The company plans to submit a Biologics License Application to the U.S. FDA for accelerated approval in the second half of 2025. Their financial results show a net loss of $152.1 million in 2024, although they have secured $593.2 million in proceeds to fund future operations. Vera's initiative to expand its development pipeline targets multiple autoimmune kidney diseases in 2025.
Read more →VERA▼ -6.1%on this newsshared move
J.P. Morgan Healthcare Conference
Vera Therapeutics recently highlighted the potential of atacicept as a first-in-class dual BAFF/APRIL B cell modulator for immunoglobulin A nephropathy (IgAN) during the J.P. Morgan Healthcare Conference. The company is focused on progressing its clinical trials, including a Phase 3 trial expected to report results in Q2 2025. Additionally, Vera showcases a robust financial standing with approximately $677 million in cash and marketable securities as they explore further indications beyond IgAN.
Read more →VERA▼ -6.1%on this newsshared move
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics has announced an exclusive license agreement with Stanford University to develop a novel dual BAFF/APRIL inhibitor, known as VT-109. This fusion protein is expected to have significant therapeutic potential for B cell mediated diseases, reflecting Vera's strategy to enhance its leadership in B cell modulation. The agreement includes undisclosed upfront and milestone payments, as Vera continues its commitment to improving treatment outcomes for patients with serious autoimmune diseases.
Read more →VERAVera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics, a late clinical-stage biotechnology firm, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to 16, 2025. The company aims to advance treatments for serious immunological diseases, showcasing its lead product candidate, atacicept. Management will also engage in one-on-one meetings with investors during the event, which could facilitate funding and collaboration opportunities.
Read more →VERAVera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
Vera Therapeutics has appointed Jason S. Carter as Chief Legal Officer to support its growth as it prepares for key developments in its clinical programs. The company anticipates announcing topline results from the ORIGIN 3 trial of atacicept for IgAN in Q2 2025, with a BLA submission expected later that year. Carter's extensive experience in biotechnology law is expected to bolster Vera's efforts to advance its lead product and other therapeutic candidates targeting serious immunological diseases.
Read more →VERAVera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
Vera Therapeutics is collaborating with the University of Michigan on the NEPTUNE Match project, which will help patients with nephrotic syndrome find relevant clinical trials, including the PIONEER study. The PIONEER study focuses on evaluating the efficacy and safety of atacicept across various autoimmune kidney diseases. This initiative aims to match patients with clinical trials based on their individual disease characteristics to optimize treatment outcomes. Initial data from the PIONEER study is expected to be announced in 2025.
Read more →VERAVera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results • Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a
Vera Therapeutics has provided a positive update on its clinical development program for atacicept, noting successful 96-week eGFR stabilization data presented at ASN Kidney Week 2024. The company has completed enrollment for the pivotal Phase 3 ORIGIN 3 trial, with topline data anticipated in the second quarter of 2025. Additionally, Vera is expanding the atacicept program to include autoimmune kidney diseases and has strengthened its finances with a $345 million equity offering. The latest financial report shows increased net losses year-over-year, which presents some challenges as the company moves forward.
Read more →VERA▲ +15.2%on this newsshared move
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Long-term improvements obse
Vera Therapeutics has announced positive results from its ORIGIN Phase 2b trial of atacicept for treating immunoglobulin A nephropathy (IgAN). The trial demonstrated sustained stabilization of kidney function over 96 weeks, indicating the drug's potential to prevent kidney failure for patients with this condition. The findings were presented at the American Society of Nephrology Kidney Week 2024 and suggest a favorable safety profile. Vera plans to advance to a Phase 3 trial with results expected in Q2 2025.
Read more →VERAVera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple
Vera Therapeutics has announced an expansion of its atacicept development program, focusing on autoimmune kidney diseases, particularly IgA nephropathy (IgAN). The company aims to leverage positive clinical data from its ORIGIN Phase 2b and 3 clinical trials, expanding the treatment to a larger IgAN population and other related conditions. This expansion reflects Vera's confidence in atacicept's potential to transform treatment outcomes in immunological diseases. Vera anticipates presenting further data at the upcoming American Society of Nephrology Kidney Week 2024.
Read more →VERAVera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
Vera Therapeutics announced that it will present long-term results from the ORIGIN Phase 2b trial of atacicept for IgAN at the ASN Kidney Week 2024. The late-breaking oral presentation will be delivered by Jonathan Barratt, while two additional posters will cover related trials. Atacicept has demonstrated significant clinical results and received FDA Breakthrough Therapy Designation. The company is also planning an R&D Day to discuss its expanded activities in New York.
Read more →VERA▲ +6.9%on this news
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
Vera Therapeutics will host an R&D Day in New York on October 2, 2024, to discuss the potential expansion of indications for its drug atacicept. The event will feature prominent experts in nephrology who will share insights on the ongoing research and development activities around atacicept. The R&D Day is strategically scheduled ahead of the expected 96-week data release from the Phase 2b ORIGIN study, which has shown promising results in treating immunoglobulin A nephropathy (IgAN). Atacicept has already received FDA Breakthrough Therapy Designation for IgAN treatment, indicating its potential to significantly improve patient outcomes.
Read more →VERA▼ -5.1%on this newsshared move
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
Vera Therapeutics has successfully completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept for immunoglobulin A nephropathy (IgAN). The enrollment of 200 participants will help support the trial's primary efficacy endpoint, with topline results anticipated in Q2 2025. The company is also set to present 96-week data from a Phase 2b trial in Q4 2024, highlighting the potential of atacicept as a transformative treatment for IgAN. Atacicept was granted Breakthrough Therapy Designation by the FDA, reflecting its promising therapeutic benefits.
Read more →VERAVera Therapeutics to Participate at September Investor Conferences
Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in upcoming investor conferences in September 2024. The company aims to showcase its innovative therapies targeting serious immunological diseases, including its lead candidate atacicept. The Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference are key events where the management team will also engage in one-on-one meetings with investors. These appearances reflect the company’s proactive approach to investor relations and its commitment to advancing treatment options in immunology.
Read more →VERAVera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results • Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN) • Presented data from Pha
Vera Therapeutics reported a strong business update, including receiving FDA Breakthrough Therapy Designation for atacicept in treating IgA nephropathy (IgAN). The company presented positive results from the Phase 2b ORIGIN study, showing significant benefits for patients over 72 weeks. They are on schedule to complete enrollment in the pivotal Phase 3 ORIGIN 3 trial by Q3 2024, with topline data expected in Q2 2025. Financially, Vera reported a net loss for the quarter, but maintains sufficient cash to support operations through potential commercialization.
Read more →VERAVera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
Vera Therapeutics has appointed David L. Johnson as Chief Operating Officer, effective immediately. Johnson brings over 30 years of experience in the biopharmaceutical industry and previously served as Chief Commercial Officer at Global Blood Therapeutics. The company is preparing for upcoming clinical data releases for their investigational drug atacicept, which is focused on treating IgAN. The appointment occurs as Vera aims to advance atacicept towards a potential market launch amidst promising trial results and FDA Breakthrough Therapy Designation.
Read more →VERAVera Therapeutics Appoints Christy J. Oliger to Board of Directors
Vera Therapeutics has appointed Christy J. Oliger to its board of directors, effective June 7, 2024. Oliger brings over 30 years of biopharmaceutical experience, including leadership roles in multiple public company boards and significant product launches. Vera Therapeutics aims to advance its lead product candidate, atacicept, for treating IgAN and other autoimmune diseases, positioning itself for potential commercial success.
Read more →VERAVera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Vera Therapeutics, a biotechnology firm specializing in treatments for immunological diseases, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference from June 10-13, 2024. CEO Marshall Fordyce will present on June 12 and the management team will engage in one-on-one investor meetings. The company aims to develop innovative biopharmaceuticals like atacicept and MAU868 to address significant healthcare needs in autoimmune diseases and viral infections.
Read more →VERAVera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
Vera Therapeutics has been granted Breakthrough Therapy Designation by the FDA for its drug atacicept to treat Immunoglobulin A Nephropathy (IgAN). This designation is based on promising data from the Phase 2b ORIGIN trial showing that atacicept may significantly improve kidney function. The company is preparing to announce long-term data from this trial later in 2024, aiming for submission for regulatory approval in 2025. The investigational drug shows potential to outperform current therapies in stabilizing kidney function for IgAN patients.
Read more →VERAVera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
Vera Therapeutics has announced promising findings from its Phase 2b ORIGIN study of atacicept in patients with immunoglobulin A nephropathy (IgAN). The data, presented at the 61st European Renal Association Congress, indicate that atacicept achieved stable kidney function and led to significant hematuria improvements over a 72-week period. With a favorable safety profile and a high retention rate, these results suggest that atacicept could potentially alter the disease course in IgAN. Full 96-week data is expected by the fourth quarter of 2024, as the company progresses toward a pivotal Phase 3 trial.
Read more →VERA▼ -5.8%on this news
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of
Vera Therapeutics recently provided a business update and reported its financial results for Q1 2024. The company showcased positive 72-week data from its Phase 2b ORIGIN clinical trial, which demonstrates sustained reduction in kidney inflammation and preservation of kidney function in patients with IgAN. Additionally, Vera has strengthened its financial position with a $287.5 million financing, anticipating further clinical data releases in 2024 and 2025. Despite a reported net loss during the quarter, Vera remains optimistic about its drug development and future milestones, including a Phase 3 trial enrollment completion.
Read more →VERAVera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
Vera Therapeutics announced that two oral presentations regarding its investigational drug atacicept will be made at the 61st European Renal Association Congress (ERA24). These presentations will detail findings from the Phase 2b ORIGIN clinical trial focused on treating IgA nephropathy. Notably, the data includes a well-regarded abstract demonstrating atacicept's effects on proteinuria and hematuria. This recognition underscores the potential impact of atacicept in transforming treatment options for patients with serious immunological diseases.
Read more →VERAVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN
Vera Therapeutics has reported strong financial results and positive data from its Phase 2b ORIGIN clinical trial for atacicept, demonstrating sustained kidney function in patients with IgA Nephropathy (IgAN). The company is expanding its Phase 3 ORIGIN 3 study, with topline data expected in the first half of 2025. Additionally, a successful financing round has bolstered the company's financial position, enabling further advancement of its pipeline. These developments suggest a promising future for Vera's lead candidate in treating IgAN.
Read more →VERAVera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
Vera Therapeutics, Inc. will participate in the 44th Annual TD Cowen Health Care Conference from March 4th to 6th in Boston, MA. The company's management, including the Chief Medical Officer and CEO, will present details about their innovative treatments for serious immunologic diseases, particularly their lead product, atacicept. The event provides an important platform for Vera to engage with investors and discuss advancements in their therapeutic approaches. A replay of the conference will be available for 90 days via their website.
Read more →VERAVera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in the 6th Annual Guggenheim Biotechnology Conference on February 7-8, 2024. The management team will engage in a fireside chat and offer one-on-one meetings with investors. This conference marks a significant opportunity for the company to showcase its developments in treatments for serious immunological diseases, including its lead product candidate, atacicept. Vera's strategic focus on advancing innovative therapies may attract further investment and attention from the healthcare community.
Read more →VERAVera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Vera Therapeutics announced the completion of an upsized public offering, closing with gross proceeds of approximately $287.5 million from the sale of 9,274,194 shares of Class A common stock. This included the full exercise of underwriters' options to purchase an additional 1,209,677 shares. The proceeds will support Vera's development of transformative treatments for serious immunologic diseases, including its lead product candidate, atacicept. The offering was managed by J.P. Morgan, TD Cowen, and Evercore ISI, signaling strong market interest in Vera's initiatives.
Read more →VERAVera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Vera Therapeutics has announced the pricing of an upsized public offering of 8,064,517 shares of its Class A common stock at $31.00 per share. This move is expected to generate approximately $250 million in gross proceeds to support its development of treatments for serious immunologic diseases. The offering is set to close on February 1, 2024, subject to customary conditions. Vera is focusing on advancing its lead product candidate, atacicept, which targets autoimmune diseases.
Read more →VERA▲ +48.7%on this news· ran to +103% by day 3shared move
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy Participants treated with atacicept for 72 weeks showed consistent and sustained re
Vera Therapeutics announced positive results from the 72-week open label extension of its Phase 2b ORIGIN trial for atacicept in IgA nephropathy patients. Participants showed sustained reductions in Gd-IgA1, hematuria, and UPCR, alongside stable eGFR, indicating potential disease modification. Switching from placebo to atacicept halted eGFR decline, and safety data suggest the drug was well-tolerated. The results bolster confidence in the ongoing Phase 3 ORIGIN 3 trial.
Read more →VERA▲ +16.7%on this news
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
Vera Therapeutics announced the appointment of Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer to strengthen its leadership team. Both appointments are aimed at advancing the company's drug development strategy, particularly for atacicept, which is currently undergoing Phase 3 trials for IgA nephropathy. Dr. Brenner has over 25 years of experience in nephrology and biotechnology, while Mr. Turner has nearly 30 years of experience in drug development and commercialization. This move signals Vera's commitment to enhance its clinical development programs and ultimately improve patient outcomes in autoimmune diseases.
Read more →VERA▲ +16.7%on this news
Corporate Presentation January 2024 2023 VERA THERAPEUTICS, INC. Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Com
Vera Therapeutics presented forward-looking statements concerning atacicept's potential as a leading treatment for IgA Nephropathy (IgAN). The company is currently conducting a Phase 3 clinical trial and expects to release significant results, including a 72-week report slated for January 25, 2024. Financially, Vera holds a robust cash position aimed at sustaining operations focused on IgAN through 2026. However, there are inherent risks related to clinical trial outcomes and regulatory approvals that the company acknowledges.
Read more →VERA▲ +16.7%on this news
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
Vera Therapeutics has announced an upcoming in-person R&D Day on January 25, 2024, where data from the Phase 2b ORIGIN clinical trial of atacicept will be presented. The trial demonstrated statistically significant and clinically meaningful reductions in proteinuria for patients with IgA nephropathy (IgAN). Leading nephrologists like Dr. Richard Lafayette and Dr. Jonathan Barratt will discuss these results, which indicate potential for atacicept as a transformative treatment option for patients with a high unmet medical need due to IgAN.
Read more →VERAVera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics, Inc. has announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, which will take place from January 7 to 11, 2024, in San Francisco, CA. The company's management will present on January 9th and will hold one-on-one meetings with investors. Vera specializes in developing transformative therapies for serious immunological diseases, with its lead product candidate being atacicept, aimed at treating diseases like IgAN and lupus nephritis.
Read more →VERAVera Therapeutics Provides Business Update and Reports Third Quarter Financial Results • Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enr
Vera Therapeutics recently provided a business update and released its financial results for Q3 2023. The company is actively enrolling patients in the Phase 3 ORIGIN 3 trial for atacicept, which targets IgA nephropathy (IgAN). Notably, new data from the Phase 2b ORIGIN trial presented at ASN Kidney Week 2023 demonstrated marked improvements in key efficacy measures, including resolution of hematuria in most patients. Additionally, Vera's financials indicate a strong cash position anticipated to support operations into early 2026.
Read more →VERAVera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Vera Therapeutics presented positive data from the Phase 2b ORIGIN study for its investigational drug atacicept at the ASN Kidney Week 2023. The analysis showed that 80% of patients receiving 150 mg of atacicept experienced resolution of hematuria after 36 weeks, a significant improvement over the placebo group. The study also noted substantial reductions in serum Gd-IgA1 levels, indicating a potential decrease in kidney disease progression risk. Vera is currently enrolling patients for a pivotal Phase 3 trial, which aims to assess the safety and efficacy of atacicept in treating IgAN.
Read more →VERA▲ +8.3%on this news
Vera Therapeutics Scheduled to Present at November Investor Conferences
Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in two investor conferences scheduled for November 2023. The management team will present at the Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference and the 6th Annual Evercore ISI HealthCONx Conference. Vera Therapeutics is advancing treatments for serious immunological diseases, including its lead candidate atacicept, which addresses autoimmune diseases. The presentations will be available for replay on their website.
Read more →VERAVera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Vera Therapeutics announced the inclusion of three abstracts on its drug candidate, atacicept, at the American Society of Nephrology Kidney Week 2023. The abstracts highlight findings from the ORIGIN 3 pivotal Phase 3 study and Phase 2b study, indicating atacicept's potential as a long-term treatment for immunoglobulin A nephropathy (IgAN). Additional results indicate that atacicept reduces serum Gd-IgA1, a biomarker linked to IgAN outcomes, and maintains protective immunity against certain infections.
Read more →VERA▼ -5.7%on this news
Vera Therapeutics Scheduled to Present at September Investor Conferences
Vera Therapeutics, Inc. is set to present and hold one-on-one meetings at four investor conferences in September 2023. These include the Citi 18th Annual BioPharma Conference and the H.C. Wainwright 25th Annual Global Investment Conference, among others. The company's focus is on transformative treatments for serious immunological diseases, with its leading candidate atacicept targeting conditions such as IgAN and lupus nephritis. Vera is also developing MAU868, a treatment for BK virus infection, further highlighting its ongoing commitment to addressing patient needs.
Read more →VERA▲ +6.2%on this news
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results • Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical
Vera Therapeutics has provided a business update and reported its financial results for the second quarter of 2023, showcasing positive data from the Phase 2b ORIGIN clinical trial of atacicept for IgAN. The trial results indicated a significant reduction in proteinuria and stabilized eGFR over 36 weeks. The company has initiated a pivotal Phase 3 trial, ORIGIN 3, and indicated financial strength to support operations into early 2026, despite reporting an increased net loss compared to the previous year.
Read more →VERA▲ +16.9%on this news· ran to +34% by day 3
Corporate Presentation June 2023 2023 VERA THERAPEUTICS, INC. Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Compan
Vera Therapeutics, Inc. has highlighted its lead clinical-stage asset, atacicept, which targets B cells and is aimed at treating IgA Nephropathy (IgAN). The company has received positive support from the FDA to advance atacicept into pivotal Phase 3 development, with expected topline data in 2026. Financially, Vera has approximately $197M in cash, allowing it to fund operations through the projected timeline. The potential annual market opportunity for this therapy is estimated to be between $6-10 billion across the US, EU, and Japan.
Read more →VERA▲ +16.9%on this news· ran to +34% by day 3shared move
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
Vera Therapeutics presented positive results from its Phase 2b ORIGIN clinical trial of atacicept for IgA nephropathy at the 60th ERA Congress. The data indicated a 43% mean reduction in proteinuria and stabilization of eGFR at week 36 for the 150 mg dose group compared to placebo. Atacicept was reported to be well-tolerated with a safety profile similar to placebo. The company has initiated a Phase 3 clinical trial, ORIGIN 3, to further assess atacicept's efficacy and safety in high-risk patients.
Read more →VERAVera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
Vera Therapeutics announced it will host a presentation featuring week 36 data from the Phase 2b ORIGIN clinical trial of atacicept for treating IgA nephropathy on June 20, 2023. The trial demonstrated promising results, having met its primary endpoint with a significant reduction in proteinuria at 24 weeks. The event will be led by Dr. Richard Lafayette, detailing the clinical trial findings including dosage effects and patient safety data.
Read more →VERAVera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Vera Therapeutics, Inc. announced its participation in the 44th Annual Goldman Sachs Global Healthcare Conference from June 12 to 15, 2023. The management team, including CEO Marshall Fordyce and CFO Sean Grant, will engage in a fireside chat on June 14. The company specializes in developing treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting autoantibodies related to autoimmune conditions.
Read more →VERAVera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
Vera Therapeutics has announced the initiation of the pivotal Phase 3 clinical trial (ORIGIN 3) for atacicept, targeting IgA nephropathy (IgAN). The trial is based on positive results from a previous Phase 2b trial regarding the efficacy of atacicept in reducing proteinuria in patients. This double-blind, placebo-controlled study aims to evaluate the treatment's safety and its impact on kidney function. Vera plans to share additional results from the earlier trial later in 2023 and 2024.
Read more →VERAVera Therapeutics Provides Business Update and Reports First Quarter Financial Results • 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clini
Vera Therapeutics announced a business update and first-quarter financial results, highlighting promising 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which has been selected for late-breaking presentation at the ERA Congress 2023. The company plans to initiate a pivotal Phase 3 trial in the second quarter of 2023 and maintains a strong balance sheet with adequate funding through early 2026. However, the firm reported a net loss of $30.1 million for the quarter, a significant increase from the previous year's loss.
Read more →VERAVera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
Vera Therapeutics has appointed Kerry Cooper, M.D., as Senior Vice President of Medical Affairs, reporting to Chief Medical Officer Celia Lin. Dr. Cooper brings nearly 40 years of experience in nephrology and medical affairs from positions at companies like AstraZeneca and Amgen. His role will focus on overseeing medical affairs strategy and advancing the development of atacicept, which is entering a pivotal Phase 3 trial for IgA nephropathy patients. The company anticipates that Dr. Cooper's expertise will support their mission of developing transformative treatments for serious immunological diseases.
Read more →VERAVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results • Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which show
Vera Therapeutics announced positive interim results from its Phase 2b ORIGIN clinical trial for atacicept, demonstrating a 41% reduction in proteinuria among IgAN patients. The company is preparing to advance atacicept into a Phase 3 clinical trial set to begin in the second quarter of 2023, supported by a strong financial position. Despite reporting a net loss of $89.1 million in 2022, Vera has adequate funding to support its operations through early 2026. The upcoming 36-week data release is eagerly anticipated and may further validate atacicept's therapeutic potential.
Read more →VERAVera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Vera Therapeutics, a late-stage biotechnology company, will participate in the Cowen 43rd Annual Health Care Conference from March 6 to 8, 2023, in Boston, MA. The company's management team will host a fireside chat and conduct one-on-one investor meetings. Vera is focused on advancing treatments for serious immunological diseases, including its lead candidate atacicept and MAU868, a monoclonal antibody that targets BK Virus infection. The event emphasizes the company's commitment to engaging with the investment community.
Read more →VERAVera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
Vera Therapeutics has announced the commencement of a public offering of $75 million in Class A common stock, which is subject to market conditions. Underwriters will have a 30-day option to purchase an additional 15% of the shares. The offering follows a shelf registration statement previously filed with the SEC. Vera is focused on developing treatments for serious immunological diseases, with its lead product candidate being atacicept, a therapy targeting autoimmune diseases.
Read more →VERA▼ -6.1%on this news· ran to -18% by day 3shared move
Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements contained in this presentation regarding ma
Vera Therapeutics has provided an update on its Phase 2b clinical trial of atacicept, a therapy for IgA nephropathy (IgAN). The company reported positive data, demonstrating a significant reduction in urine protein-to-creatinine ratio (UPCR) and a favorable safety profile compared to placebo. Vera plans to initiate Phase 3 trials in the first half of 2023, highlighting atacicept's potential as a best-in-class treatment for IgAN. Despite these positive results, the company cautions that actual outcomes may vary due to regulatory and clinical risks.
Read more →VERA▼ -6.1%on this news· ran to -18% by day 3shared move
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
Vera Therapeutics has released a 36-week interim analysis of its Phase 2b clinical trial for atacicept in patients with IgA nephropathy, indicating a significant 48% reduction in proteinuria in the 150 mg dose group compared to placebo. The company plans to advance atacicept to a pivotal Phase 3 trial in the first half of 2023, contingent on discussions with the FDA. The drug is considered a promising candidate for treating this serious condition, which lacks effective treatments.
Read more →VERAVera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
Vera Therapeutics, a biotechnology company, announced a virtual key opinion leader (KOL) webinar to discuss the updates on atacicept for IgA nephropathy (IgAN). Dr. Jonathan Barratt from the University of Leicester will present the findings from the ORIGIN Phase 2b trial. This multinational study evaluates atacicept's efficacy in patients with persistent proteinuria at high risk of disease progression. The company believes that atacicept may represent a best-in-class treatment option in this therapeutic area.
Read more →VERA▼ -5.4%on this news· ran to -72% by day 3
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Vera Therapeutics announced positive topline results from the Phase 2b ORIGIN clinical trial of atacicept for treating IgA nephropathy (IgAN). The trial met its primary endpoint, showing a statistically significant mean reduction in proteinuria at 24 weeks, particularly in the 150 mg dose group. Safety results indicated that atacicept was well tolerated, with a low discontinuation rate due to adverse events. Vera plans to move forward with a Phase 3 trial in the first half of 2023, pending discussions with regulatory authorities.
Read more →VERAVERA THERAPEUTICS, INC. Phase 2b Clinical Trial Week 24 Results January 2023 Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "ou
2023 VERA THERAPEUTICS, INC. Phase 2b Clinical Trial Week 24 Results January 2023 Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements contained in this
Read more →VERAVera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s
Read more →VERAVera Therapeutics to Present at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s
Read more →VERAVera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
Dr. Barratt will discuss disease burden and pathogenesis of IgAN, a common cause of kidney failure and a high unmet medical need globally Event held Monday, November 28, 2022 at 2pm ET BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a
Read more →VERA▼ -6%on this news
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results • Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy (IgAN) topline data planned to be presented in early Q1
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results -Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy (IgAN) topline data planned to be presented in early Q1 2023 -Initiated the pivotal Phase 3 COMPASS clinical trial of atac
Read more →VERAVera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting
New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN) Atacicept is the first therapeutic to show reduction in all of the three first hits of IgAN pathogenesis – serum galactose-deficient IgA1 (Gd-IgA1
Read more →VERAVera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting
BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuri
Read more →VERA▲ +5.9%on this news
Vera Therapeutics to Present at Upcoming Conferences in September 2022
BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s
Read more →VERA▲ +9%on this news· ran to +21% by day 3
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results • Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results -Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1 2023 -Presented positive 12-week interim
Read more →VERAVera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s
Read more →VERAVera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
BRISBANE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced completion of patien
Read more →VERAVera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremia Data presented as oral late breaker at American Transplant Congress BK Virus is a leading cause of transplant loss and transplant-associated morbidity; currently no
Read more →VERAVera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s
Read more →VERAVera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease progression New analysis shows atacicept improved renal function in patients with mild-to-mode
Read more →VERAVera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results • Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 • Init
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results -Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 -Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, fo
Read more →VERAVera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, following positive clinical strategy meeting with FDA earlier this year Results from a 12-week i
Read more →VERAVera Therapeutics to Present at Upcoming Conferences in May 2022
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s m
Read more →VERA▼ -5.7%on this newsshared move
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus
BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced two oral presentation
Read more →VERAVera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data fro
Read more →VERAVera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors
BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M
Read more →VERAVera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results • Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 • Acquired MAU868, a
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results -Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 -Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim anal
Read more →VERAVera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2
Read more →VERA▼ -7.3%on this newsshared move
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
Management to provide overview of MAU868, its lead asset in the treatment of BK Virus infections in kidney transplant patients BK Virus is a leading cause of transplant loss and transplant-associated morbidity KOL webinar to be held Tuesday, March 29, 2022 BRISBANE, Calif., Ma
Read more →VERAVera Therapeutics to Host Business Update Call
BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call a
Read more →VERAVera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall
Read more →VERAVera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its public
Read more →VERAVera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase
Read more →VERAVera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall F
Read more →VERA▲ +11.4%on this news
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of transplant loss and transplant-associated morbidity BRISBANE, Calif., Dec. 17, 2021 (G
Read more →VERA▲ +11.4%on this news
subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as plans, will, anticipates, goal, potential, and similar expression
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 B
Read more →VERAVera Therapeutics Announces Appointment of Kimball Hall to Board of Directors
BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment
Read more →VERA▼ -6.6%on this news
Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that
Read more →VERA▼ -6.6%on this news
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in
Read more →VERA▼ -6.6%on this news
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update  Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly d
Read more →VERA▼ -6.6%on this news· ran to +32% by day 3
Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021
Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent manner up to 72 weeks New quartile-based analysis of JANUS results showed ataci
Read more →VERAVera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today the upcoming presentation of cli
Read more →VERAVera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today that it is scheduled to host a
Read more →VERAVera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, today reported its financial results for the sec
Read more →VERAVera Therapeutics Appoints Sean Grant as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the
Read more →VERAVera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update - - - Completed an initial public offering with net proceeds, including the exercise of the underwriters
Therapeutics Reports First Quarter 2021 Financial Results and Provides initial public offering with net proceeds, including the exercise of the underwriters option in full, of approximately $48.4 million in May 2021 Expanded the management team to support initiation of ataci
Read more →VERAVera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4 million in May 2021 Expanded the management team to support initiation of atacicept clinical development program Initiated Phase 2b ORIGIN
Read more →VERAVera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that
Read more →VERAVera Therapeutics Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing
Read more →Competitive Position
How VERA ranks across every disease it competes inCompetitive Position is a premium feature
See how VERA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial